SLC5A2 and chronic kidney disease: In T2DM patients with mild to moderate CKD and HbA1cabove target despite dual therapy, TRIPLE THERAPY with metformin, SGLT2 and an alternative AD (replacing GLP1-RA) is recommended to improve blood glucose control.